Posted by Michael Wonder on 10 Nov 2020
Rafael Pharmaceuticals receives FDA fast track designation for CPI-613 (devimistat) for the treatment of pancreatic cancer
10 November 2020 - Rafael Pharmaceuticals announced today that the U.S. FDA has granted fast track designation for the Company’s lead compound, CPI-613 (devimistat), for the treatment of metastatic pancreatic cancer.
The Company also recently announced that the FDA granted devimistat orphan drug designation for the treatment of soft tissue sarcoma.
